

# Data Sharing Statement

Kazandjian. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-Risk Smoldering Myeloma. *JAMA Oncol.* Published September 16, 2021. doi:10.1001/jamaoncol.2021.3971

## Data

**Data available:** Yes

**Data types:** Deidentified participant data

**How to access data:** De-identified individual participant data which underlies the results reported in this Article and the study protocol will be available from 7 years after publication because of ongoing research, and subject to sponsor approval. Data will be made available to investigators who develop methodologically sound proposals. Proposals should be directed to the corresponding author.

**When available:** beginning date: 04-08-2028

## Supporting Documents

**Document types:** Informed consent form

**How to access documents:** Contact Corresponding Author

**When available:** With publication

## Additional Information

**Who can access the data:** researchers whose proposed use of the data has been approved

**Types of analyses:** for any purpose

**Mechanisms of data availability:** signed data access agreement